- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Type 2 diabetes mellitus (T2DM)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Semaglutide – November 2019
Semaglutide: Injection 2 mg in 1.5 mL pre-filled syringe, Injection 4 mg in 3 mL pre-filled syringe; Ozempic®
Last updated
6 March 2020